Article
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2007
Yoshida Kimihide, Yatabe Yasushi, Park Ji Young, Shimizu Junichi, Horio Yoshitsugu, Matsuo Keitaro, Kosaka Takayuki, Mitsudomi Tetsuya, Hida Toyoaki
Abstract excerpt
INTRODUCTION: We evaluated the efficacy of gefitinib monotherapy prospectively in patients with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. METHODS: Patients with NSCLC were examined for EGFR exon 19 deletion mutations by fragment analysis and for EGFR L858R point mutations by the Cycleave polymerase chain reaction technique. EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.